Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.34 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651344 | 0.82 | LSS (0.39) | LSSPLA2G2AHDAC4HTTHDAC1 | |
| SCHEMBL2655940 | 0.79 | PLA2G2A (0.42) | PLA2G2AHDAC1HDAC6EPHX2NR1H4 | |
| SCHEMBL2651609 | 0.79 | PLA2G2A (0.44) | PLA2G2AHDAC1HDAC6EPHX2NR1H4 | |
| SCHEMBL2655938 | 0.74 | HDAC1 (0.46) | LSSPLA2G2AHTTHDAC1HDAC6 | |
| SCHEMBL13800570 | 0.73 | CA1 (0.50) | HSP90AA1HDAC1HDAC6CA2TMEM97 | |
| SCHEMBL2644845 | 0.72 | CA1 (0.53) | HDAC6CA2EPHX2NR1H4 | |
| SCHEMBL2651773 | 0.71 | EPHX2 (0.41) | HDAC6EPHX2NR1H4 | |
| Hydrochloric Acid SCHEMBL2644250 | 0.71 | CA1 (0.52) | HDAC6CA2EPHX2NR1H4 | |
| SCHEMBL13800527 | 0.69 | ALDH1A1 (0.47) | HSP90AA1ALDH1A1HDAC1HDAC6 | |
| SCHEMBL13800529 | 0.68 | GCGR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LSS 2509/4885PLA2G2A 1428/4885HSP90AA1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.